RecruitingNot ApplicableNCT07329699

Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial)

Artificial Intelligence-Driven Angiography-Based Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI


Sponsor

Samsung Medical Center

Enrollment

2,100 participants

Start Date

Mar 18, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The AIM-FFR trial is a prospective, multi-center, open-label, randomized controlled, non-inferiority trial. The current trial will evaluate non-inferiority of MPFFR-guided PCI, compared with invasive FFR-guided PCI in patients with coronary artery disease.


Eligibility

Min Age: 19 Years

Inclusion Criteria5

  • Subject must be at least 19 years of age
  • Eligible for coronary angiography and/or percutaneous coronary intervention.
  • Chronic coronary syndrome or acute coronary syndrome (non-culprit vessels only)
  • Coronary artery disease in one or more native major epicardial vessels or their branches with reference vessel diameter of at least 2.5mm and with visually assessed coronary stenosis in which the physiological severity of the lesion is questionable (typically 40-90% diameter stenosis).
  • Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily.

Exclusion Criteria14

  • Patients unable to provide informed consent
  • Patients with known intolerance to aspirin, P2Y12 inhibitors, or components of drug-eluting stents and drug-coated balloons
  • Patients with coronary artery bypass grafting
  • Patients who have non-cardiac co-morbid conditions with life expectancy <1 year
  • Patients with cardiogenic shock or cardiac arrest
  • Patients with severe left ventricular systolic dysfunction (ejection fraction <30%)
  • Patients with severe valvular heart disease requiring open heart surgery
  • Pregnant or lactating women
  • Culprit vessel of patients with ST-elevation myocardial infarction (target lesions in non-culprit vessel can be enrolled)
  • Chronic total occlusion (target lesions in vessels without chronic total occlusion can be enrolled)
  • Ostial stenosis in left man coronary artery or right coronary artery
  • Severe tortuosity of any target vessel
  • Severe overlap in the stenosed segment
  • Poor image quality precluding identification of vessel contours

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTMPFFR or Invasive FFR

Functionally significant stenosis will be defined as MPFFR≤0.80 or FFR≤0.80. For lesions with MPFFR≤0.80 or FFR≤0.80, PCI will be recommended under current guidelines, however, final decision regarding PCI will be at the discretion of operators. In the MPFFR-guided PCI group, on-site MPFFR value will be used in decision making of revascularization. If PCI is not performed for lesions with MPFFR≤0.80 or FFR≤0.80, the specific reasons will be collected in electronic case report form. For lesions with MPFFR\>0.80 or FFR\>0.80, PCI will be deferred.


Locations(23)

Korea University Anam Hospital

Seoul, Select State, South Korea

Inje University Haeundae Paik Hospital

Busan, South Korea

Changwon Fatima Hospital

Changwon, South Korea

Gyeongsang National University Changwon Hospital

Changwon, South Korea

Keimyung University Dongsan Hospital

Daegu, South Korea

Kyungpook National University Hospital

Daegu, South Korea

Chonnam National University Hospital, Chonnam National University Medical School

Gwangju, South Korea

Chung-Ang University Gwangmyeong Hospital

Gwangmyeong, South Korea

CHA Bundang Medical Center

Gyeonggi-do, South Korea

Wonkwang University Hospital

Iksan, South Korea

Inje University College of Medicine, Ilsan Paik Hospital

Ilsan, South Korea

Gachon University Gil Medical Center

Incheon, South Korea

International St. Mary's Hospital

Incheon, South Korea

Gyeongsang National University Hospital

Jinju, South Korea

Seoul National University Bundang Hospital

Seongnam, South Korea

Samsung Medical Center

Seoul, South Korea

Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

Seoul, South Korea

Korea University Guro Hospital

Seoul, South Korea

Seoul National University Boramae Medical Center

Seoul, South Korea

Ajou University Hospital

Suwon, South Korea

Uijeongbu ST. Mary's Hospital

Uijeongbu-si, South Korea

Ulsan University Hospital

Ulsan, South Korea

Wonju Severance Christian Hospital

Wŏnju, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07329699


Related Trials